LAVA Therapeutics N.V. (LVTX)
LAVA Therapeutics Statistics
Share Statistics
LAVA Therapeutics has 26.31M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 26.31M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 24.11% |
| Shares Floating | 13.02M |
| Failed to Deliver (FTD) Shares | 250 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 387.25K, so 1.47% of the outstanding shares have been sold short.
| Short Interest | 387.25K |
| Short % of Shares Out | 1.47% |
| Short % of Float | 2.97% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -1.02 and the forward PE ratio is -1.09. LAVA Therapeutics's PEG ratio is 0.03.
| PE Ratio | -1.02 |
| Forward PE | -1.09 |
| PS Ratio | 2.13 |
| Forward PS | 0.5 |
| PB Ratio | 0.92 |
| P/FCF Ratio | -1.3 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for LAVA Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.4, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.4 |
| Quick Ratio | 4.4 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | -57.66 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $352.41K |
| Profits Per Employee | $-738.65K |
| Employee Count | 34 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -630K |
| Effective Tax Rate | 2.45% |
Stock Price Statistics
The stock price has increased by -60.55% in the last 52 weeks. The beta is 0.45, so LAVA Therapeutics's price volatility has been higher than the market average.
| Beta | 0.45 |
| 52-Week Price Change | -60.55% |
| 50-Day Moving Average | 1.18 |
| 200-Day Moving Average | 1.49 |
| Relative Strength Index (RSI) | 42.47 |
| Average Volume (20 Days) | 413.4K |
Income Statement
In the last 12 months, LAVA Therapeutics had revenue of 11.98M and earned -25.11M in profits. Earnings per share was -0.94.
| Revenue | 11.98M |
| Gross Profit | 11.98M |
| Operating Income | -29.69M |
| Net Income | -25.11M |
| EBITDA | -23.5M |
| EBIT | -23.97M |
| Earnings Per Share (EPS) | -0.94 |
Balance Sheet
The company has 35.02M in cash and 395K in debt, giving a net cash position of 34.62M.
| Cash & Cash Equivalents | 35.02M |
| Total Debt | 395K |
| Net Cash | 34.62M |
| Retained Earnings | -174.97M |
| Total Assets | 80.83M |
| Working Capital | 61.29M |
Cash Flow
In the last 12 months, operating cash flow was -19.54M and capital expenditures -23K, giving a free cash flow of -19.57M.
| Operating Cash Flow | -19.54M |
| Capital Expenditures | -23K |
| Free Cash Flow | -19.57M |
| FCF Per Share | -0.73 |
Margins
Gross margin is 100%, with operating and profit margins of -247.81% and -209.6%.
| Gross Margin | 100% |
| Operating Margin | -247.81% |
| Pretax Margin | -214.86% |
| Profit Margin | -209.6% |
| EBITDA Margin | -196.14% |
| EBIT Margin | -247.81% |
| FCF Margin | -163.3% |
Dividends & Yields
LVTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LVTX is $2, which is 75.4% higher than the current price. The consensus rating is "Hold".
| Price Target | $2 |
| Price Target Difference | 75.4% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -2.62 |
| Piotroski F-Score | 3 |